Caspase-12 Inhibitor Z-ATAD-FMK

Caspase-12 Inhibitor Z-ATAD-FMK is a synthetic peptide-based irreversible inhibitor designed to selectively target caspase-12, a cysteine protease implicated in endoplasmic reticulum (ER) stress-induced apoptosis and inflammatory signaling pathways. As a fluoromethyl ketone (FMK) derivative, Z-ATAD-FMK covalently binds to the active site of caspase-12, effectively blocking its enzymatic activity. This compound is highly valued in cellular and molecular biology research for its ability to dissect the specific contributions of caspase-12 in programmed cell death and immune responses, providing a precise tool for mechanistic studies of ER stress and related cellular processes.

Apoptosis Research: Z-ATAD-FMK is widely employed in studies investigating the molecular mechanisms of apoptosis, particularly those involving ER stress. By inhibiting caspase-12, researchers can delineate the specific signaling cascades and downstream effectors associated with ER stress-induced apoptotic pathways. This selective inhibition allows for the identification of caspase-12-dependent and -independent cell death events, supporting the elucidation of complex cellular responses to various stressors such as unfolded protein accumulation or calcium dysregulation.

Inflammatory Pathway Analysis: The inhibitor is instrumental in exploring the role of caspase-12 in modulating inflammatory responses. Caspase-12 has been reported to negatively regulate the activation of certain inflammatory caspases, influencing cytokine processing and secretion. Utilizing Z-ATAD-FMK in immune cell models enables researchers to assess how caspase-12 inhibition alters the balance of pro- and anti-inflammatory mediators, contributing to a deeper understanding of innate immune regulation and the cellular basis of inflammation.

Neurodegeneration Studies: In neurobiology, Z-ATAD-FMK is applied to investigate the involvement of ER stress and caspase-12 activation in neurodegenerative processes. Accumulating evidence links ER stress-induced apoptosis to neuronal loss in conditions such as Alzheimer's disease and amyotrophic lateral sclerosis. By selectively inhibiting caspase-12, scientists can assess its contribution to neuronal vulnerability and survival, thereby clarifying the mechanistic underpinnings of neurodegenerative disease progression in relevant cell and tissue models.

Cellular Stress Response Characterization: The compound is also useful for dissecting cellular adaptation to ER stress beyond apoptosis. Caspase-12 activity is intertwined with the unfolded protein response (UPR), a critical adaptive mechanism that restores ER homeostasis. Application of Z-ATAD-FMK allows researchers to parse out the non-apoptotic roles of caspase-12, such as its influence on UPR signaling, protein quality control, and cell fate decisions under chronic stress conditions.

Drug Discovery and Screening: Z-ATAD-FMK serves as a reference inhibitor in high-throughput screening assays designed to identify novel modulators of caspase-12 or related proteases. Its well-characterized mechanism of action and selectivity profile make it an ideal positive control for validating assay performance or benchmarking the efficacy of new candidate compounds. This application supports the development of targeted therapeutics and research tools aimed at modulating ER stress and apoptosis pathways in a variety of experimental systems.

1. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

2. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

3. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

4. Exosomes-mediated Transfer of miR-125a/b in Cell-to-cell Communication: A Novel Mechanism of Genetic Exchange in the Intestinal Microenvironment

5. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma